RevenanasBook a free audit

IPO

Corxel plans SPAC merger with Amanat Acquisition to fund oral obesity drug CX11 through phase 3

Biotech

IPO

Key Facts

Signal Type

IPO

Industry

Biotech

Companies

Corxel Pharmaceuticals, Amanat Acquisition, TCGX, Vincentage, TriGemX Bio

Date

What Happened

Corxel Pharmaceuticals, a biotech focused on oral GLP-1 obesity drugs, agreed in principle to merge with SPAC Amanat Acquisition. The deal includes $75 million held by the SPAC plus $300 million in PIPE financing from top healthcare investors including RA Capital, NEA, SR One, and TCGX. The combined company will trade under a new name on the Nasdaq, targeted to close in the first half of 2026.

Who Is Affected

Corxel’s U.S. entity and its obesity assets are directly affected; the Shanghai-based parent retains rights to CX11 in Asia. Investors in the PIPE (TCGX, NEA, SR One, LifeSci Venture Partners, RA Capital) now have significant ownership stakes. Current and potential vendors supporting Phase 3 clinical development—such as CROs, eTMF providers, and clinical operations software vendors—will see immediate demand as enrollment kicks off in Q1 2026.

Market Impact

With $375 million in total cash, Corxel estimates its funding runway extends through 2029. Key implications:

  • Competitive pressure in the obesity/GLP-1 space: CX11 showed 11.5% weight loss at 36 weeks, positioning it against orforglipron (Eli Lilly) and other oral GLP-1s.
  • Phase 3 start triggers spending on clinical trial infrastructure, regulatory submissions, and investor communications.
  • SPAC route compresses the public-market timeline, meaning IR and compliance vendors must scale quickly.

What to Watch

Phase 3 enrollment initiation (expected Q1 2026) will be the next major milestone. Watch for FDA alignment on trial protocol—Corxel has already engaged the agency. Also monitor how the company differentiates CX11’s safety/efficacy profile in a crowded market, and whether the SPAC merger closes on schedule in H1 2026.

Related coverage

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner